Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics
requires quantitative measurements in controlled clinical trials. We mapped genomic …

Simple Summary Existing research on predicting biochemical recurrence after prostate
surgery has been insufficient. Here, we aimed to predict biochemical recurrence after radical …

Objectives Men diagnosed with non-metastatic prostate cancer require standardised and
robust long-term prognostic information to help them decide on management. Most currently …

Prostate cancer (PCa) screening remains one of the most controversial topics in clinical and
public health. Despite being the second most common cancer in men worldwide …

Within five to ten years after radical prostatectomy (RP), approximately 15–34% of prostate
cancer (PCa) patients experience biochemical recurrence (BCR), which is defined as …

As new biomarkers, circular RNAs (circRNAs) have been largely unexplored in prostate
cancer (PCa). Using an integrative approach, we aimed to evaluate the potential of …

Abstract Background Prostate cancer (PCa) is the most common cancer in North American
men. Beyond the established contribution of androgens to disease progression, growing …

Background Biochemical recurrence (BCR) is considered a decisive risk factor for clinical
recurrence and the metastasis of prostate cancer (PCa). Therefore, we developed and …

After diagnosis of prostate cancer is confirmed by a positive biopsy, the tumor may be
surgically removed via radical prostatectomy (RP). However, many prostate cancer patients …

Purpose: We report outcomes of high-risk prostate cancer (PCa) patients, initially classified
according to a 3-tier NCCN classification system, treated with external beam radiation …